Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL
Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
A prospective, open-label, multicentre phase-II trial of ibrutinib plus venetoclax plus
obinutuzumab in physically fit (CIRS ≤ 6 & normal creatinine clearance) and unfit (CIRS > 6 &
creatinine clearance ≥ 50 ml/min) patients with previously untreated chronic lymphocytic
leukemia (CLL) with TP53 deletion (17p-) and/or mutation
Phase:
Phase 2
Details
Lead Sponsor:
University of Ulm
Collaborators:
AbbVie German CLL Study Group Janssen-Cilag Ltd. Roche Pharma AG